On the 13th, silver fell by 1.91%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract silver was 2,502, up or down by -1.91%, with a turnover of 1,004,900 lots. The position data showed that the top 20 seats were net, and the difference position was 30,444 lots. The total turnover of silver futures contracts was 1,505,900 lots, an increase of 417,500 lots over the previous day. The first 20 seats in the contract held 335,600 lots, a decrease of 15,200 lots from the previous day. The short positions in the top 20 seats of the contract were 251,300 lots, an increase of 17,500 lots over the previous day. (Sina Futures)On the 13th, SSE 50 index futures fell by 2.58%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, SSE 50 index futures closed at 2,412, up or down by -2.58%, with a turnover of 53,000 lots. The position data showed that the top 20 seats were clear, and the difference position was 7,398 lots. The total number of contracts of SSE 50 index futures was 91,500 lots, an increase of 25,700 lots over the previous day. The first 20 seats in the contract held 88,200 lots, an increase of 2,257 lots over the previous day. The short positions in the top 20 seats of the contract were 113,700 lots, an increase of 1,701 lots over the previous day. (Sina Futures)Yiwei lithium can pass the medical device quality management system certification (ISO 13485:2016). Yiwei lithium news, recently, Yiwei lithium can obtain the medical device quality management system certification (ISO 13485:2016) issued by DNV, and the certification scope includes the design, manufacture and sales of lithium batteries and secondary lithium batteries for medical devices. It indicates that Yiwei lithium can reach the international level in research and development, manufacturing and quality management of medical battery products.
Huichuan Technology's newly established subsidiary contains a number of AI businesses. The enterprise search APP shows that Beijing Huichuan Technology Co., Ltd. was recently established with Guo Lipeng as the legal representative and a registered capital of 300 million yuan. Its business scope includes: artificial intelligence theory and algorithm software development; Basic resources and technical platform of artificial intelligence; General application system of artificial intelligence; Artificial intelligence application software development, etc. Enterprise investigation shows that the company is wholly owned by Huichuan Technology.Ministry of Finance of Thailand: It is estimated that the global minimum corporate tax of 15% will be implemented from January 2025.Huichuan Technology's newly established subsidiary contains a number of AI businesses. The enterprise search APP shows that Beijing Huichuan Technology Co., Ltd. was recently established with Guo Lipeng as the legal representative and a registered capital of 300 million yuan. Its business scope includes: artificial intelligence theory and algorithm software development; Basic resources and technical platform of artificial intelligence; General application system of artificial intelligence; Artificial intelligence application software development, etc. Enterprise investigation shows that the company is wholly owned by Huichuan Technology.
The concept of first-round economy continued to increase the daily limit of more than 10 constituent stocks, and the concept of first-round economy continued to increase in intraday trading. Media games, IP economy, performing arts and travel, and Meta-Universe all rose well. More than 10 constituent stocks such as Aofei Entertainment, Lisheng Sports, Dafeng Industry, Tianxiaxiu, and Roman shares rose by more than 10%.Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.The turnover of Shanghai and Shenzhen stock markets exceeded 1 trillion yuan for the 53rd consecutive trading day.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14